Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it mattersMarkus Ketteler, Mary B. Leonard, Marc Vervloet et al.|Kidney International|2017Cited by 998
Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysisCsaba P. Kövesdy, H. Lester Kirchner, Kunihiro Matsushita et al.|European Heart Journal|2018Cited by 323
Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline UpdateMarkus Ketteler, Mary B. Leonard, Geoffrey A. Block et al.|Annals of Internal Medicine|2018Cited by 316
Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patientsJunichiro James Kazama, Masafumi Fukagawa, Fuminori Sato et al.|Kidney International|2005Cited by 132
Uremic Toxicity and Bone in CKDSuguru Yamamoto, Masafumi Fukagawa|Journal of Nephrology|2017Cited by 62